1. Home
  2. LXRX vs CLBR Comparison

LXRX vs CLBR Comparison

Compare LXRX & CLBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXRX
  • CLBR
  • Stock Information
  • Founded
  • LXRX 1995
  • CLBR 2023
  • Country
  • LXRX United States
  • CLBR United States
  • Employees
  • LXRX N/A
  • CLBR N/A
  • Industry
  • LXRX Biotechnology: Pharmaceutical Preparations
  • CLBR
  • Sector
  • LXRX Health Care
  • CLBR
  • Exchange
  • LXRX Nasdaq
  • CLBR Nasdaq
  • Market Cap
  • LXRX 124.4M
  • CLBR 230.6M
  • IPO Year
  • LXRX 2000
  • CLBR 2023
  • Fundamental
  • Price
  • LXRX $0.36
  • CLBR $10.59
  • Analyst Decision
  • LXRX Buy
  • CLBR
  • Analyst Count
  • LXRX 4
  • CLBR 0
  • Target Price
  • LXRX $3.67
  • CLBR N/A
  • AVG Volume (30 Days)
  • LXRX 9.5M
  • CLBR 151.4K
  • Earning Date
  • LXRX 03-06-2025
  • CLBR 01-01-0001
  • Dividend Yield
  • LXRX N/A
  • CLBR N/A
  • EPS Growth
  • LXRX N/A
  • CLBR N/A
  • EPS
  • LXRX N/A
  • CLBR 0.27
  • Revenue
  • LXRX $31,081,000.00
  • CLBR N/A
  • Revenue This Year
  • LXRX N/A
  • CLBR N/A
  • Revenue Next Year
  • LXRX $101.91
  • CLBR N/A
  • P/E Ratio
  • LXRX N/A
  • CLBR $39.08
  • Revenue Growth
  • LXRX 2481.48
  • CLBR N/A
  • 52 Week Low
  • LXRX $0.28
  • CLBR $10.15
  • 52 Week High
  • LXRX $2.62
  • CLBR $12.28
  • Technical
  • Relative Strength Index (RSI)
  • LXRX 32.86
  • CLBR 34.66
  • Support Level
  • LXRX $0.33
  • CLBR $10.54
  • Resistance Level
  • LXRX $0.41
  • CLBR $10.61
  • Average True Range (ATR)
  • LXRX 0.06
  • CLBR 0.07
  • MACD
  • LXRX -0.02
  • CLBR 0.01
  • Stochastic Oscillator
  • LXRX 16.38
  • CLBR 19.23

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

About CLBR Colombier Acquisition Corp. II

Colombier Acquisition Corp II is a blank check company.

Share on Social Networks: